Prelude Therapeutics (PRLD) Total Current Liabilities (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Total Current Liabilities data on file, last reported at $41.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 110.85% year-over-year to $41.7 million; the trailing twelve-month figure through Mar 2026 stood at $41.7 million (up 110.85% YoY), and the FY2025 full-year result was $53.0 million, up 106.68% from the prior year.
• Total Current Liabilities fell to $41.7 million in Q1 2026, from $53.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $53.0 million in Q4 2025 to a low of $15.2 million in Q2 2023.
• A 5-year average of $23.0 million and a median of $20.9 million in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities decreased 21.65% in 2023 and soared 110.85% in 2026, its largest moves.
• Tracing PRLD's Total Current Liabilities over 5 years: stood at $21.7 million in 2022, then rose by 0.59% to $21.8 million in 2023, then rose by 17.46% to $25.6 million in 2024, then soared by 106.68% to $53.0 million in 2025, then declined by 21.27% to $41.7 million in 2026.
• Business Quant data shows PRLD's Total Current Liabilities at $41.7 million in Q1 2026, $53.0 million in Q4 2025, and $18.2 million in Q3 2025.